NLS Pharmaceutics Amends Private Placement Agreement
Ticker: NCEL · Form: 6-K · Filed: Jun 30, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: private-placement, amendment, securities
TL;DR
NLS amended its private placement deal from March, issued 1.2M preferred shares.
AI Summary
On June 26, 2025, NLS Pharmaceutics Ltd. amended its Securities Purchase Agreement from March 27, 2025, related to a private placement. The initial closing under this agreement involved the issuance of 1,212,122 preferred shares at a par value of CHF 0.03 per share.
Why It Matters
This amendment to the securities purchase agreement could impact the company's capital structure and future financing plans.
Risk Assessment
Risk Level: low — The filing is a routine update on a previously disclosed private placement agreement.
Key Numbers
- 1,212,122 — Preferred Shares Issued (Issued as part of the private placement under the amended agreement.)
- CHF 0.03 — Par Value per Share (The nominal value of each preferred share issued.)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- June 26, 2025 (date) — Amendment date
- March 27, 2025 (date) — Original agreement date
- 1,212,122 (dollar_amount) — Number of preferred shares issued
- CHF 0.03 (dollar_amount) — Par value per preferred share
FAQ
What are the key terms of the amendment to the Securities Purchase Agreement?
The filing states that an amendment was executed on June 26, 2025, to the Securities Purchase Agreement initially executed on March 27, 2025, relating to a private placement offering. Specific details of the amendment's terms are not fully elaborated in the provided text.
How many preferred shares were issued in the initial closing?
The company issued 1,212,122 preferred shares in the initial closing contemplated by the Securities Purchase Agreement.
What is the par value of the preferred shares issued?
The par value of the preferred shares issued is CHF 0.03 per share.
When was the original Securities Purchase Agreement executed?
The original Securities Purchase Agreement was executed on March 27, 2025.
What is the principal executive office address of NLS Pharmaceutics Ltd.?
The principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 30, 2025 regarding NLS Pharmaceutics Ltd. (NCEL).